AstraZeneca announced that its drug Tezspire met all primary and key secondary goals in a late-stage trial for eosinophilic esophagitis, a chronic condition causing inflammation and difficulty swallowing. The trial involved 368 patients who received either low or high doses of Tezspire or a placebo, with both doses significantly reducing inflammation and improving swallowing over 52 weeks. Tezspire, already approved for severe asthma and chronic sinus disease, works by blocking a protein that triggers inflammation. This success is significant as the condition affects over 470,000 people in the U.S., many of whom do not respond well to current treatments.
AstraZeneca has priced a €2.55 billion bond issuance split into four fixed-rate tranches maturing between 2030 and 2038. The bonds, issued by its US subsidiary and guaranteed by the parent company, carry coupons ranging from 3.402% to 4.169%, reflect...
AstraZeneca faced a setback with the discontinuation of its volrustomig trial for non-small cell lung cancer, but strong clinical results for drugs like Tagrisso and Enhertu support its growth prospects. Investment firm CICC gave AstraZeneca an "Outp...
